Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi/Aventis Merger Will Not Affect Exubera, Actonel Agreements – Sanofi

Executive Summary

Sanofi-Synthelabo does not expect merging with Aventis would negatively affect Aventis' co-promotion agreements for Actonel and Exubera, CEO Jean-Francois Dehecq said during a March 11 investor call
Advertisement

Related Content

Aventis Cites Plavix Patent Litigation In Countering Sanofi’s Takeover Bid
Aventis Cites Plavix Patent Litigation In Countering Sanofi’s Takeover Bid
Aventis Would Provide Critical Mass For Sanofi’s Mid-Term R&D – Sanofi CEO
Exubera May Be Wild Card In Sanofi Bid For Aventis; Genta Deal Unaffected
Exubera May Be Wild Card In Sanofi Bid For Aventis; Genta Deal Unaffected
Advertisement
UsernamePublicRestriction

Register

PS043540

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel